Gynion is developing a proprietary ablative gel platform designed to simplify selected gynecologic procedures and shift them from the operating room into the office. Our goal is to provide millions of women worldwide with safe, effective, and accessible office-based therapies for common gynecologic conditions, reducing the procedural barriers that often limit access to treatment.

Menorrx™ is Gynion’s lead product candidate for the treatment of heavy menstrual bleeding (HMB). Menorrx is a one-time, non-hormonal endometrial ablation gel therapy designed to shift definitive treatment for HMB from hospitals and ambulatory surgical centers into the gynecology office. The proprietary ablative gel is delivered through a small, flexible catheter and is designed to eliminate the need for capital equipment, cervical dilation, and advanced anesthesia.

Gynion is also developing Clarablex™, an ablative gel therapy for cervical intraepithelial neoplasia (CIN), the precancerous cervical lesions caused by persistent HPV infection. Clarablex is designed as a simple, single-treatment therapy applied directly to the cervix without capital equipment or advanced anesthesia, with the potential to enable a single-visit approach to cervical cancer prevention.